Mira Pharmaceuticals

Mira Pharmaceuticals | 1,002 followers on LinkedIn. Developing the next-generation FDA-approved novel synthetic THC analog | MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the adverse side effects of cannabis plant extracts.

Mira1a: A New Breakthrough in the World of Pharmaceutical Cannabinoids - Cannabis Tech

Amendment to Employment Agreement, dated October 13, 2023, between, MIRA PHARMACEUTICALS, INC., Business Contracts

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

Erez Aminov - Chief Executive Officer at Mira Pharmaceuticals, Inc.

MIRAPRO 15 MG Tab, MIRTAZAPINE, SQUARE PHARMACEUTICALS LIMITED

formdrsa_016.jpg

MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast

MIRA, MIRALOGX sign agreement for depression therapy

MIRA Pharmaceuticals Set to Disrupt Cannabis and Pharma Markets with Nasdaq

Catalogue - Medlife Pharmaceuticals in Mira Road East, Thane - Justdial

MIRA Pharmaceuticals, Inc. (MIRA) Stock Price, Quote & News - Stock Analysis